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Hepatitis C virus (HCV) infection is a major cause of hepatocellular carcinoma (HCC) and 
chronic liver disease worldwide. Recent developments and advances in HCV replication 
systems in vitro and in vivo, transgenic animal models, and gene expression profiling 
approaches have provided novel insights into the mechanisms of HCV replication. They 
have also helped elucidate host cellular responses, including activated/inactivated signaling 
pathways, and the relationship between innate immune responses by HCV infection and 
host genetic traits. However, the mechanisms of hepatocyte malignant transformation 
induced by HCV infection are still largely unclear, most likely due to the heterogeneity of 
molecular paths leading to HCC development in each individual. In this review, we 
summarize recent advances in knowledge about the mechanisms of hepatocarcinogenesis 






Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third 
leading cause of cancer death worldwide 1. The majority of HCCs arise from a background 
of chronic liver diseases caused by infection with hepatitis B virus (HBV) or hepatitis C 
virus (HCV) 2. Although both viruses are hepatotropic and regarded as causative agents of 
HCC, the underlying mechanisms of hepatocarcinogenesis are considered to be largely 
different, partly due to differences in the nature of DNA viruses (with an integration 
capacity for the host genome) and RNA viruses (with no genome integration capacity).  
HCV is an RNA virus that is unable to integrate into the host genome but, instead, 
its proteins interact with various host proteins and induce host responses that potentially 
contribute to the malignant transformation of cells. In addition, HCC usually develops in 
the setting of liver cirrhosis after long-term continuous inflammation/regeneration 
processes; these accelerate the turnover of hepatocytes with increased risk of replication 
errors and DNA damage. Furthermore, recent genome-wide association studies have 
suggested that the natural course of HCV infection might be modified by the genetic 
background of the host 3, 4. Thus, both host and virus factors are considered to affect the 
process of hepatocarcinogenesis in a complex manner.  
 In this review, we summarize the current knowledge of the mechanisms of 
hepatocarcinogenesis induced by HCV infection. We also focus on recent findings of 
transcriptomic characteristics of HCV-related HCC and summarize the potential signaling 




Chronic HCV infection is a major risk factor for the development of HCC worldwide. 
According to the World Health Organization (WHO), approximately 170 million people are 
chronically infected with HCV. Although epidemiological evidence has suggested a clear, 
close relationship between HCV infection and HCC, 5, 6 the prevalence of HCV infection in 
HCC patients differs noticeably between geographical regions. Thus, HCV infection is 
found in 70–80% of HCC patients in Japan, 70% in Egypt, 40–50% in Italy and Spain, 
about 20% in the United States (US), and less than 10% in China 7-9. In industrialized 
countries including the US, a recent increase in HCC incidence and mortality has been 
observed, potentially due to the rising incidence of HCV infection transmitted through 
contaminated blood 10.  
 HCV increases the risk of HCC by promoting inflammation and fibrosis of the 
infected liver that eventually results in liver cirrhosis. Once HCV-related cirrhosis is 
established, HCC develops at an annual rate of about 4–7% 11. Other factors including 
alcohol intake, diabetes, and obesity have also been reported to increase the risk of HCC 
development by about 2-4 fold, indicating a strong life-style effect on the process of 
hepatocarcinogenesis 12, 13. Age and male gender are also contributing risk factors for HCV-






Virus proteins and host responses 
HCV belongs to the Flaviviridae family. It has a positive-stranded linear RNA genome of 
about 9.6-kb containing a single large open reading frame encoding three structural (core, 
E1, and E2) and seven non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) 
proteins 14. The structural proteins form the HCV virions whereas non-structural proteins 
are involved in the processes of viral replication, assembly, and maturation. HCV proteins 
are known to be processed by host and viral proteases. Both structural and non-structural 
proteins can interact with various host cellular proteins to potentially promote the malignant 
transformation of hepatocytes (see recent reviews 7, 15, 16). In this review, because of space 
limitations, we focus on the findings of core and NS5A proteins in terms of host responses 
potentially evoked during the process of HCV-related hepatocarcinogenesis. 
Core protein 
HCV core is a 21 kDa nucleocapsid protein with an RNA-binding capacity. In addition to 
its function in regulating HCV-RNA translation and HCV particle assembly, core protein is 
known to be involved in mediating the alteration of various host cell signaling pathways, 
transcriptional activation, modulation of immune responses, apoptosis, oxidative stress, and 
lipid metabolism 7. Several recent studies have indicated the statistically significant high 
frequency of mutations in the core gene in HCV-infected patients who developed HCC 17, 18. 
However, the functional relevance of mutant core proteins on the malignant transformation 
of hepatocytes or the HCV life cycle has yet to be clarified.  
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 Evidence of core protein as a causative agent of HCC was initially obtained from 
the transgenic mice model in which core gene overexpression, under the regulation of the 
HBV regulatory element used as a promoter, resulted in steatosis of mouse livers in early 
life, with subsequent development of adenoma and HCC 19. However, another mouse 
model using a different promoter and of a different strain background resulted only in 
steatosis or different phenotypes without HCC development 20, 21. Similar controversial 
findings were reported in transgenic mice expressing HCV polyprotein or structural protein 
with regards to the development of HCC 22, 23. Thus, the role of core protein alone in the 
development of HCC remains unclear in transgenic mouse models. 
 Although the direct role of core protein in the malignant transformation of 
hepatocytes is still under investigation, it seems to be related to the development of hepatic 
steatosis 19, 24. Indeed, steatosis is one of the risk factors for the development of HCV-
related HCC 25, 26, and activation of the lipogenic pathway has been reported in a subset of 
HCC cases 27. Core protein is associated with the surface of lipid droplets in infected cells 
and might be directly related to steatosis through several factors responsible for lipid 
biogenesis and degradation, including peroxisome proliferator-activated receptor alpha and 
sterol-regulatory element binding protein-1 21, 28-30. Furthermore, core protein is reported to 
interact with endoplasmic reticulum (ER) or mitochondrial outer membranes and induce 
ER stress by perturbation of protein folding or by the accumulation of reactive oxygen 
species (ROS) through mitochondrial dysfunction 31, 32. ROS produced in this way might 
result in DNA damage to the host genome and accelerate the process of 
hepatocarcinogenesis. Increased hepatic iron deposition may also induce oxidative stress 
7 
 
and lipid peroxidation, thus increasing the risk of HCC development in HCV polyprotein 
transgenic mice 33. 
 Since the discovery of HCV, various studies have investigated the role of core on 
host cells. Its effects have been demonstrated on signaling pathways responsible for the cell 
cycle, and apoptosis through interaction with several tumor suppressors including p53, p73, 
and p21 34-39 as well as apoptosis regulators such as TNF-signaling or Bcl-2 members 40-
42 However, the data obtained from these studies are relatively inconsistent with each other 
and have varied across experimental models. Core protein may influence the growth and 
proliferation of host cells through activation of signaling pathways such as Raf/mitogen 
activated protein kinase (MAPK) 43, Wnt/beta catenin 16, and transforming growth factor 
beta (TGF-) 15, 44. These pathways are known to be activated in HCC 45. The findings 
therefore indicate a potential role for core in cell proliferation or suppression of apoptosis 
during malignant transformation of hepatocytes in the liver of chronic hepatitis C, where 
chronic inflammation and regeneration of hepatocytes continuously occurs. 
NS5A protein 
NS5A is a 56–58 kDa protein phosphorylated at serine residues by serine-threonine kinase 
46 and is essential for replication of the HCV genome. NS5A protein forms part of the viral 
replicase complex and is localized mainly in the cytoplasm of infected cells in association 
with the ER. NS5A can become a lower molecular weight protein through post-
translational modification, after which it can undergo translocation to the nucleus where it 
acts as a transcriptional activator. High frequencies of wild-type NS5A genes were reported 
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to be dominant in liver cirrhosis patients who finally developed HCC compared with those 
who did not 47, but the mechanistic significance of the NS5A wild/mutant genotypes in the 
process of HCV-related hepatocarcinogenesis remains uncertain.  
 NS5A protein has been suggested to interact with various signaling pathways 
including cell cycle/apoptosis 48 and lipid metabolism 28, 49, 50 in host cells and shares some 
signaling targets with core protein. NS5A is recognized as a transcriptional activator for 
many target genes 51 including p53 and its binding protein, TATA binding protein (TBP). 
Transcription factor IID activities were reported to be modified by NS5A in the suppression 
of p53-dependent transcriptional transactivation and apoptosis 52, 53. NS5A may also 
interact with pathways such as Bcl2 54, phosphatidylinositol 3-kinase (PI3-K) 55, Wnt/beta 
catenin signaling 56, and mTOR 57 to activate cell proliferation signaling and inhibit 
apoptosis.  
 Taken together, intriguing data concerning the function of core and NS5A proteins 
on host cell signaling pathways, transcriptional activation, apoptosis, oxidative stress, and 
lipid metabolism described above suggest a diverse role for HCV proteins in the 
pathophysiology of chronic hepatitis C that leads to malignant transformation in infected 
hepatocytes. Key findings and present concepts are summarized in Figure 1).  
 
Transcriptomic characteristics of HCV-related HCC 
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As described above, HCV proteins can evoke various host responses in infected cells at 
transcriptional/translational/post-translational levels. Furthermore, enhanced cell 
death/regeneration processes are considered to induce DNA damage and accelerate 
replication errors that cause frequent mutations and genomic alteration in the host genome. 
The central dogma is defined as the flow of genetic information from DNA to mRNA and 
then to protein, so genetic/genomic alterations and transcriptional/translational 
modifications are ultimately considered to affect the cellular signaling pathway at the 
transcriptional level.  
Over the past decade, several methods (including differential display, serial analysis 
of gene expression (SAGE), and microarray) have been developed to allow comparative 
studies of gene expression between normal and cancer cells on a genome-wide scale 58, and 
the analysis of a set of all RNA molecules (mainly indicating mRNAs) is termed as whole 
transcriptome analysis. Extensive transcriptome analysis of HCC and corresponding non-
cancerous livers has been performed, and the results have greatly increased our knowledge 
about the transcriptome characteristics of HCV-related HCC.  
 Early microarray and SAGE studies investigating the gene expression patterns of 
chronic hepatitis B and C tissues indicated that these two chronic hepatitis tissues had 
distinct gene expression profiles; the genes activated in chronic hepatitis C were correlated 
with signaling pathways associated with apoptosis, oxidative stress responses, and Th1 
cytokine signaling 59, 60. An early study comparing genes activated in HCV-related and 
HBV-related HCCs showed that the genes associated with xenobiotic metabolism were 
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more abundantly expressed in HCV-related HCC 61, suggesting a detoxification role which 
is potentially induced by chronic inflammation and generation of ROS resulting from HCV 
infection. In contrast, HBV-related HCC might closely correlate with the activation of 
imprint genes, including IGF-II as investigated by oligo-DNA microarray 62, suggesting a 
role of de-differentiation or epigenetic alteration of the host genome in HBV-related HCC. 
Activation of genes associated with interferon, oxidative stress, apoptosis, and lipid 
metabolism signaling was detected in HCV-related HCC and chronic hepatitis C specimens 
27, 60, 63, consistent with numerous functional studies that have investigated the host 
response evoked by HCV structural and non-structural proteins 48.  
 Transcriptome analysis has also recently shed new light on the transcriptional 
alteration events occurring in early stages of HCV-related hepatocarcinogenesis. GPC3 
(encoding Glypican 3) was identified as one of the most activated transcripts in the early 
stage of hepatocarcinogenesis 60, 64, while several recent studies showed that gene 
signatures including GPC3 can successfully discriminate HCCs from pre-malignant 
dysplastic nodules and cirrhosis nodules 65, 66. Close examination of genes differentially 
expressed among cirrhotic nodules, dysplastic nodules, and early and advanced HCV-
related HCC tissues has also suggested roles for Toll-like receptor signaling, Wnt signaling, 
BMP/TGF-signaling, JAK-STAT signaling, and DNA repair/cell cycle responses in each 
step of the malignant transformation processes 67. These processes might therefore provide 
candidate molecular targets for the chemoprevention of HCV-related HCC. 
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 Recent advances in transcriptome analysis have also provided detailed information 
on the status of small noncoding RNAs, microRNAs, that can regulate the expression of 
target genes and viral replication in normal and cancer tissues. Expression of microRNAs 
including miR-122 and -199a has been reported to modulate HCV replication 68-70, and 
miR-122 expression can be regulated by host interferon signaling and responses 71. HCV 
protein expression in turn could induce miRNAs and might affect the tumor suppressor 
DLC1 and the chemosensitivity of malignantly transformed cells 72, 73. Several microRNAs 
were also differentially expressed between HCV-related and HBV-related HCCs as well as 
their corresponding non-cancerous liver tissues. The candidate signaling pathways 
potentially altered by microRNAs in HCV-related tissues were those associated with 
antigen presentation, cell cycle, and lipid metabolism 74, consistent with the mRNA 
microarray data described above. MicroRNAs have also recently been reported to 
successfully discriminate between HCC and cirrhotic liver tissues 75, implicating their role 
in the early stages of malignant transformation. These data suggest that microRNAs may be 
good targets for the eradication of HCC as well as hepatocytes infected with HCV. 
 
Conclusion 
The heterogeneity of genetic/transcriptomic/proteomic events observed in hepatocytes or 
cell lines expressing HCV proteins and HCV-related HCCs reported thus far has suggested 
that complex mechanisms underlie malignant transformation induced by HCV infection. 
These potentially act through convoluted virus-host interactions including HCV replication 
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with host cell cycles, apoptosis, proliferation, quality control of protein synthesis, lipid 
metabolism, and DNA damage responses. Indeed, HCC is a heterogeneous disease in terms 
of drug sensitivity, metastatic capacity, and clinical outcome. The heterogeneity of HCV-
related HCC may closely correlate with the origin of malignantly transformed cells where 
multifaceted cellular reactions including apoptosis and cell proliferation are induced by 
HCV infection. An in-depth understanding of these molecular complexities associated with 
HCV-related HCC may provide the opportunity for effective chemoprevention of HCC 
among those with HCV-cirrhosis, and to design tailor-made treatment options for HCV-







Figure 1. Signaling pathways potentially affected by HCV proteins. EGF, epidermal 
growth factor; IGF, insulin-like growth factor; MAPK, mitogen activated protein kinase; 
PI3-K, phosphatidylinositol 3-kinase; ER, endoplasmic reticulum; TBP, TATA binding 
protein; PPAR, peroxisome proliferator-activated receptor; SREBP, sterol-regulatory 
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